Effect of Dexmedetomidine on Oxygenation and Lung Mechanics
Effect of Different Does of Dexmedetomidine on Oxygenation and Lung Mechanics
1 other identifier
interventional
176
1 country
1
Brief Summary
Dexmedetomidine is a selective α -2 agonist widely used in anesthesia for its sympatholytic, sedative and analgesic effects . Favorable respiratory effects in animals , and in selected human patient groups have been reported when using this agent .we investigated the effects of different doses of dexmedetomidine infusion on oxygenation
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 28, 2024
CompletedStudy Start
First participant enrolled
April 1, 2024
CompletedFirst Posted
Study publicly available on registry
April 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedApril 10, 2024
April 1, 2024
1 year
March 28, 2024
April 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Oxygenation by the end study
PaO2/Fraction of inspired oxygen
UP TO 6 HOURE
Secondary Outcomes (3)
Intraoperative dynamic lung compliance
up to 6 hours
Intraoperative static lung compliance
UP TO 6 HOURE
Physiological dead space
UP TO 6HOURE
Study Arms (3)
group A
ACTIVE COMPARATORDexmedetomidine (Precedex) loadings of 1 μg/kg than continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
group B
ACTIVE COMPARATORDexmedetomidine (Precedex) loadings of 0.5 μg/kg then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
group C
ACTIVE COMPARATORDexmedetomidine (Precedex) loadings of 0.25 μg/kg(group C) then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Interventions
Dexmedetomidine (Precedex) loadings of 1 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Dexmedetomidine (Precedex) loadings of 0.5 μg/kg , then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Dexmedetomidine (Precedex) loadings of 0.25 μg/kg, then continuously at a rate of 0.2 μg/(kg/h) till the end of the operation .
Eligibility Criteria
You may qualify if:
- Morbidly obese patients with restrictive lung disease ASA I AND II laparoscopic sleeve gastrectomy
You may not qualify if:
- history of heart failure history of cardiac arrhythmias severe liver or kidney impairment. Patients with forced expiratory volume in 1 sec (FEV1)/ FVC \< 70%
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Cairo university
Cairo, 11562, Egypt
Study Officials
- PRINCIPAL INVESTIGATOR
Amr s wahdan, MD
Cairo university , Cairo, Egypt
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
March 28, 2024
First Posted
April 10, 2024
Study Start
April 1, 2024
Primary Completion
April 1, 2025
Study Completion
May 1, 2025
Last Updated
April 10, 2024
Record last verified: 2024-04